Podium Presentations

PODIUM PRESENTATIONS
Podium Session I
Monday, May 18, 2009
3:45PM-4:45PM

HEALTH CARE DECISION-MAKER’S CASE STUDIES I
CASE1:
LESSONS LEARNED: FROM COVERAGE WITH EVIDENCE DEVELOPMENT FOR POSITRON EMISSION TOMOGRAPHY SCANS FOR ONCOLOGIC INDICATIONS 
Whicher DM, Tunis S
Center for Medical Technology Policy, Baltimore, MD, USA 
 
   
CASE2:
TOWARDS AN INTEGRATED APPROACH TO THE ASSESSMENT OF SURROGATE OUTCOME DATA
Platona A, Lopert R, Sansom L
Department of Health and Ageing, Canberra, ACT, Australia
   
CASE3:
HEALTH SERVICES PHARMACEUTICAL COVERAGE FOR COMMON DISEASES MAY BE CHALLENGED BY SIGNIFICANT RISE IN ONCOLOGY DRUG EXPENDITURE
Katzir I, Westerman-Landes J, Siegelmann-Danieli N, Kokia E, Lomnicky Y
Maccabi Healthcare Services, Tel Aviv, Israel

CANCER - OUTCOMES RESEARCH STUDIES
CN1:
RECENT ERYTHROPOIESIS-STIMULATING AGENT (ESA) UTILIZATION TREND IN CANCER CHEMOTHERAPY PATIENTS IN A MANAGED CARE AND A HOSPITAL OUTPATIENT SETTING
Lafeuille MH1, Bailey R2, Vekeman F1, Piech CT2, McKenzie RS2, Lefebvre P1
1 Groupe d'Analyse, Ltée, Montréal, QC, Canada, 2Centocor Ortho Biotech Services, LLC, Horsham, PA, USA
   
CN2:
WHEN IS CANCER CARE COST-EFFECTIVE? A SYSTEMATIC OVERVIEW OF COST-UTILITY ANALYSES IN ONCOLOGY
Greenberg D1, Earle C2, Fang C1, Eldar-Lissai A3, Neumann PJ1
1Tufts Medical Center, Boston, MA, USA, 2Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 3University of Rochester, Rochester, NY, USA
   
CN3:
ASSESSING THE MAJOR DRIVERS FOR THE INCREASED HEALTH CARE COSTS ASSOCIATED WITH COLORECTAL CANCER
Rahman M1, Weinstein R2, Wilcox M2, Matcho A2, Wong S1
1Ortho Clinical Diagnostics, Raritan, NJ, USA, 2PRD USA, Titusville, NJ, USA
   
CN4:
LEVERAGING MULTIPLE DATA SOURCES TO EVALUATE COST AND SURVIVAL IN FOLFOX OR FOLFIRI TREATED STAGE IV COLORECTAL CANCER PATIENTS
Harley C1, Seal B2, Shetty S3, Nelson M1
1i3 Innovus, Eden Prairie, MN, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA, 3UnitedHealthcare, Edina, MN, USA

DRUG UTILIZATION STUDIES
DU1:
PHYSICAL FUNCTION AND THE CONCOMITANT USE OF ANTICHOLINERGIC ANTIHISTAMINES AND CHOLINESTERASE INHIBITORS AMONG MEDICAID RECIPIENTS WITH DEMENTIA
Modi A1, Craig B1, Weiner M2, Sands L1, Thomas J1
1Purdue University, West Lafayette, IN, USA, 2Indiana University, Indiana University Center for Aging Research and Regenstrief Institute Inc, Indianapolis, IN, USA
 
DU2:
RACIAL DISPARITIES AND BARRIER TO DRUG UTILIZATION IN PATIENTS WITH DIABETES IN THE UNITED STATES
Seetasith A, Zhang JX
Virginia Commonwealth University, Richmond, VA, USA
   
DU3:
PATTERN OF UTILIZATION OF PEGFILGRASTIM IN PATIENTS WITH CHEMOTHERAPY-INDUCED NEUTROPENIA: A RETROSPECTIVE ANALYSIS OF ADMINISTRATIVE CLAIMS DATA
Vekeman F1, Laliberte F1, Afonja O2, Lafeuille MH1, Barghout V2, Duh MS3, Skarin AT4
1Groupe d'analyse, Ltee, Montréal, QC, Canada, 2Bayer HealthCare Pharmaceuticals, Inc, Wayne, NJ, USA, 3Analysis Group, Inc, Boston, MA, USA, 4Dana-Farber Cancer Institute, Boston, MA, USA
   
DU4:
THE IMPACT OF DEMOGRAPHICS AND INSURANCE ON QUALITY OF CARE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN A CALIFORNIA MEDICAID PROGRAM
Nichol MB1, Wu J1, Knight TK1, Priest JL2, Cantrell CR2
1University of Southern California, Los Angeles, CA, USA, 2GlaxoSmithKline, Research Triangle Park, NC, USA 

PERSONALIZED MEDICINE
PM1:
PERSONALIZED MEDICINE: FACTORS INFLUENCING REIMBURSEMENT
Meckley LM, Neumann PJ
Tufts Medical Center, Boston, MA, USA
   
PM2:
IMPACT OF PHARMACOGENETICS ON THE COSTS OF MANAGING ADVERSE EVENTS WITH WARFARIN: A PROSPECTIVE ANALYSIS
Hughes DA1, Al-Zubiedi S2, Hanson A2, Jorgensen A2, Pirmohamed M2
1Bangor University, Bangor, UK, 2University of Liverpool, Liverpool, UK
   
PM3:
USE OF PHARMACOGENETIC TESTING TO DETERMINE ADJUVANT HORMONAL THERAPY CHOICE IN EARLY STAGE BREAST CANCER PATIENTS: A VALUE OF INFORMATION ANALYSIS
Woods BS, Hawkins NS
Oxford Outcomes (UK), Oxford, UK
   
PM4:
AN EXPLORATION OF THE POTENTIAL CLINICAL BENEFITS AND RISKS OF CYP2D6 TESTING TO GUIDE TAMOXIFEN THERAPY IN BREAST CANCER
Veenstra DL, Lin MP, Garrison LP, Burke W
University of Washington, Seattle, WA, USA

RESEARCH ON METHODS - UTILITY METHODS
UT1:
ON THE ISSUE OF UTILITY MULTIPLICATION: A REVISIT
Fu AZ
Cleveland Clinic, Cleveland, OH, USA
   
UT2:
ELICITING TIME TRADE-OFF AMOUNTS FOR HEALTH STATES IN HYPOTHETICAL INDIVIDUALS OF DIFFERENT AGES USING A DISCRETE CHOICE EXPERIMENT
Prosser LA1, Rusinak D2, Payne K3, Shi P2, Uyeki TM4, Messonnier M4
1University of Michigan, Ann Arbor, MI, USA, 2Harvard Pilgrim Health Care and Harvard Medical School, Boston, MA, USA, 3University of Manchester, Manchester, UK, 4Centers for Disease Control and Prevention, Atlanta, GA, USA
   
UT3:
THE VALUE OF ADDED LIFE YEARS AS A FUNCTION OF AGE, PROGNOSIS AND QUALITY OF LIFE
van Hout BA
Pharmerit Ltd, York, North Yorkshire, UK
   
UT4:
SOCIAL PREFERENCES FOR EQ-5D HEALTH STATES : IS IT TIME TO CALL “TIMEOUT” ON TTO?
Bailey HH1, Kind P2
1University of the West Indies, St. Augustine, Trinidad and Tobago, 2University of York, York, UK
Podium Session II
Monday, May 18, 2009
5:00PM-6:00PM
HEALTH CARE DECISION-MAKER’S CASE STUDIES II
CASE4:
DIABETES PHYSICIAN RECOGNITION IN A LARGE HEALTH PLAN
Kramer M1, Perez HE2, Stacy T2
1Aetna, Brunswick, MD, USA, 2Total Therapeutic Management Inc, Kennesaw, GA, USA
   
CASE5:
PHARMACOECONOMIC APPLICATIONS IN FORMULARY MANAGEMENT: A CASE STUDY OF ERLOTINIB AT A MAJOR CANCER CENTER
Lal LS1, Ugwu C2, DaCosta Byfield S1, Miller LA1, Arbuckle R1
1University of Texas M.D. Anderson Cancer Center, Houston, TX, USA, 2University of Houston, Houston, TX, USA
   
CASE6:
PILOT PROJECT: INTEGRATING ADMINISTRATIVE AND FINANCIAL DATABASES TO ESTIMATE PRICE OF HOSPITALIZATIONS 
Wong H1, Levit K2, Sun YC3
1Agency for Healthcare Research and Quality, Rockville, MD, USA, 2Thomson Reuters/Agency for Healthcare Research and Quality, Washington, DC, USA, 3Thomson Reuters, Santa Barbara, CA, USA

RESEARCH ON METHODS - COST & CLINICAL OUTCOMES METHODS
CO1:
EVIDENCE-BASED TIME HORIZON FOR THE INTERVENTIONS IN PHARMACOECONOMIC MODELS
Farahani P
Berkshire Medical Center, University of Massachusetts Medical School, Pittsfield, MA, USA
   
CO2:
METHODS: FOR INTERPRETING AND DISPLAYING RESULTS: FROM REGRESSION MODELS: BEYOND BETAS AND ODDS RATIOS
Ganz M
Abt Bio-Pharma Solutions, Inc. and Harvard School of Public Health, Lexington, MA, USA
   
CO3:
ESTIMATING DRUG COSTS IN ECONOMIC EVALUATIONS IN IRELAND AND THE UK: AN ANALYSIS OF PRACTICE AND RESEARCH RECOMMENDATIONS
Hughes DA1, Tilson L2, Drummond MF3
1Bangor University, Bangor, UK, 2National Centre for Pharmacoeconomics, Dublin, Ireland, 3University of York, York, Heslington, UK
   
CO4:
COMPARISON OF INPATIENT COST ESTIMATION METHODS: USING DATA FROM A CYSTIC FIBROSIS TRIAL
Dinan M1, Morgan Dewitt E2, Grussemeyer C1, Reed SD1
1Duke Clinical Research Institute, Durham, NC, USA, 2Duke University, Durham, NC, USA

CARDIOVASCULAR DISORDERS - OUTCOMES RESEARCH STUDIES
CV1:
ASSOCIATION OF CARDIOMETABOLIC RISK FACTORS AND PREVALENT CARDIOVASCULAR EVENTS
Malone DC1, Boudreau D2, Nichols G3, Raebel MA4, Fishman P5, Feldstein A3, Ben-Joseph R6, Okamoto LJ7
1University of Arizona College of Pharmacy, Tucson, AZ, USA, 2United BioSource Corporation, Seattle, WA, USA, 3Kaiser Permanente, Portland, OR, USA, 4Kaiser Permanente Colorado, Denver, CO, USA, 5Group Health, Seattle, WA, USA, 6Sanofi-Aventis, Bridgewater, NJ, USA, 7United BioSource Corporation, Bethesda, MD, USA
   
CV2:
COMPARISON OF CARDIOVASCULAR EVENT RATES IN SUBJECTS WITH TYPE-2 DIABETES MELLITUS WHO AUGMENTED FROM STATIN MONOTHERAPY TO STATIN PLUS FIBRATE COMBINATION THERAPY WITH THOSE WHO REMAINED ON STATIN MONOTHERAPY
Suh HS, Doctor JN
University of Southern California, Los Angeles, CA, USA
   
CV3:
THE IMPACT OF PROTON PUMP INHIBITORS ON CARDIOVASCULAR-RELATED EVENT COSTS IN PATIENTS INITIATING CLOPIDOGREL
Aubert RE, Stanek EJ, Yao J, Frueh FW, Teagarden JR, Epstein RS
Medco Health Solutions, Inc, Franklin Lakes, NJ, USA
   
CV4:
ASPIRIN VERSUS CLOPIDOGREL IN COMBINATION WITH PROTON-PUMP INHIBITORS FOR PREVENTION OF RECURRENT PEPTIC ULCER COMPLICATIONS IN PATIENTS WITH PREVIOUS GASTROINTESTINAL BLEEDING
Hsiao FY1, Tsai YW2, Huang WF3, Wen YW4, Chen PF4, Chang PY3, Kuo KN4
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2National Health Research Institutes, Zhunan Town, Taiwan, 3National Yang-Ming University, Taipei, Taiwan, 4National Health Research Institutes, Miaoli County, Taiwan

FORMULARY DEVELOPMENT STUDIES
FD1:
PREFERRED DRUG BENEFIT PLAN FOR CIVIL SERVANT MEDICAL BENEFIT SCHEME IN THAILAND: A CONJOINT ANALYSIS
Ngorsuraches S, Tanvejsilp P
Prince of Songkla University, Hatyai, Songkhla, Thailand
   
FD2:
ORPHAN DRUGS' MARKET ACCESS IN THE UNITED STATES
Doyle JJ1, Sepulveda B2
1Quintiles Consulting, Hawthorne, NY, USA, 2Global Market Access, Quintiles Consulting, Hawthorne, NY, USA
   
FD3:
CONCEPTUAL ISSUES IN THE DEVELOPMENT OF A MEASURE OF FORMULARY CULTURE
Duhig J1, Edison M1, Galanter W1, Koronkowski M1, Lambert BL1, Lodolce A1, Pickard AS2, Wilke CT2, Schiff G3
1University of Illinois at Chicago, Chicago, IL, USA, 2College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA, 3Brigham and Women's Hospital, Boston, MA, USA
   
FD4:
THE EFFECTS OF NICE HTAS ON DRUG PRESCRIBING AND EXPENDITURES IN THE UNITED STATES
Sepulveda B1, Doyle JJ2
1Global Market Access, Quintiles Consulting, Hawthorne, NY, USA, 2Quintiles Consulting, Hawthorne, NY, USA

VACCINATION - OUTCOMES RESEARCH STUDIES
VA1:
A MARKOV MODEL EXAMINING THE PUBLIC HEALTH IMPACT AND COST-EFFECTIVENESS OF MASS VACCINATION USING LIVE ATTENUATED HUMAN ROTAVIRUS VACCINE IN A DEVELOPING ASIAN COUNTRY
Rose J1, Molnar RL1, Watts B2, Singer ME1
1Case Western Reserve University School of Medicine, Cleveland, OH, USA, 2Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH, USA
   
VA2:
COST EFFECTIVENESS ANALYSIS OF THE NEW 10-VALENT PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN-D CONJUGATE VACCINE (PHID-CV) IN CANADA
Ismaila AS1, Pereira JA1, Robson RC1, Simpson SD1, Rawson NS1, Standaert BA2
1GlaxoSmithKline, Mississauga, ON, Canada, 2GlaxoSmithKline Biologicals, Rixensart, Belgium
   
VA3:
A GLOBAL COST-EFFECTIVENESS EVALUATION OF THE IMPACT OF POTENTIAL INNOVATIONS IN MEASLES VACCINATION
Garrison LP1, Bauch CT2, Bresnahan BW1, Hazlet TK1, Kadiyala S1, Veenstra DL1
1University of Washington, Seattle, WA, USA, 2University of Guelph, Guelph, ON, Canada
   
VA4:
COMPARING COST-EFFECTIVENESS RESULTS: OF A CROSS-SECTIONAL POPULATION MODEL WITH A COHORT MODEL: THE APPLICATION TO PNEUMOCOCCAL CONJUGATE VACCINATION
Demarteau N, Standaert B
GlaxoSmithKline Biologicals, Rixensart, Belgium
Podium Session III
TUESDAY, May 19, 2009
8:30AM-9:30AM

COMPLIANCE STUDIES
CM1:
ASSOCIATION BETWEEN INSURANCE GAPS AND ANTI-HYPERTENSION MEDICATION ADHERENCE IN A NATIONAL REPRESENTATIVE SAMPLE IN THE UNITED STATES
Gai Y1, Gu NY2
1Babson College, Babson Park, MA, USA, 2University of Southern California, Los Angeles, CA, USA
   
CM2:
UTILIZATION AND PERSISTENCE OF ALISKIREN IN A REAL-WORLD ENVIRONMENT
Zeng F1, Lau H2, Hanson K2, Patel BV1, Gao S1
1MedImpact Healthcare Systems, Inc, San Diego, CA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
   
CM3:
THE IMPACT OF MEDICARE PART D ON ELDERLY PATIENTS' COMPLIANCE WITH STATINS
Zhang D, Henderson SC, Denarie MF
IMS Health, Blue Bell, PA, USA
   
CM4:
NONADHERENCE TO CLINICAL PRACTICE GUIDELINES FOR MULTIPLE DISEASE CONDITIONS IN A CALIFORNIA MEDICAID POPULATION
Nichol MB1, Knight TK1, Priest JL2, Wu J1, Cantrell CR2
1University of Southern California, Los Angeles, CA, USA, 2GlaxoSmithKline, Research Triangle Park, NC, USA

DIABETES - OUTCOMES RESEARCH & HEALTH CARE POLICY STUDIES
DB1:
PROJECTED COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 IN TYPE 2 DIABETES PATIENTS SWITCHED FROM BIPHASIC HUMAN INSULIN IN THE UNITED STATES
Aagren M1, Thomsen TL2, Knudsen VK3
1Novo Nordisk Inc, Princeton, NJ, USA, 2Novo Nordisk A/S, Virum, Denmark, 3Novo Nordisk A/S, Bagsvaerd, Denmark
   
DB2:
ANTI-HYPERTENSIVE DRUG USE AND RISK OF DEMENTIA IN PATIENTS WITH DIABETES MELLITUS (DM)
Johnson ML1, Parikh NM2, Kunik M3, Schulz P4, Chen H1, Aparasu R1, Yadav R1, Morgan R5
1University of Houston, Houston, TX, USA, 2Analysis Group Inc, Boston, MA, USA, 3Center of Quality of Care and Utilization Studies, Veterans Affairs Medical Center, Houston, TX, USA, 4Baylor Neurology, Houston, TX, USA, 5University of Texas, Houston, TX, USA
   
DB3:
DIRECT AND INDIRECT COSTS ASSOCIATED WITH DIABETES PATIENTS WITH AND WITHOUT MACROVASCULAR COMORBIDITIES IN THE UNITED STATES
Qiu Y1, Fu AZ2, Radican L1
1Merck & Co., Inc, Whitehouse Station, NJ, USA, 2Cleveland Clinic, Cleveland, OH, USA
   
DB4:
COST OF DIABETIC-RELATED COMPLICATIONS AND CARDIOVASCULAR EVENTS BY TYPE OF EVENT AND SETTING ANNUALLY FOR THE FIRST THREE YEARS FOLLOWING ITS ONSET
Simons WR1, Hagan MA2
1Global Health Economics & Outcomes Research, Inc, Summit, NJ, USA, 2Daiichi-Sankyo, Wayne, NJ, USA

HEALTH TECHNOLOGY ASSESSMENT
HT1:
ANALYSIS OF FACTORS ASSOCIATED WITH REIMBURSEMENT DECISION MAKING IN HEALTH TECHNOLOGY ASSESSMENT (HTA)
Bending MW1, Kruger J1, Hutton J1, McGrath C2
1University of York, York, North Yorkshire, UK, 2Pfizer Inc, Surrey, UK
   
HT2:
HEALTH TECHNOLOGY ASSESSMENT - A COMPREHENSIVE FRAMEWORK FOR EVIDENCE-BASED RECOMMENDATIONS IN ONTARIO
Johnson A1, Sikich N2, Evans G1, Evans W3, Giacomini M4, Glendining M5, Krahn MD6, Levin L7, Oh PI8, Perera C2
1Queen's University, Kingston, ON, Canada, 2Ministry of Health and Long Term Care, Toronto, ON, Canada, 3Juravinski Cancer Centre, Hamilton, ON, Canada, 4McMaster University, Hamilton, ON, Canada, 5Hamilton Health Sciences, Hamilton, ON, Canada, 6University Health Network, Toronto, ON, Canada, 7Ontario Ministry of Health and LongTerm Care, Toronto, ON, Canada, 8Toronto Rehabilitation Institute, North York, ON, Canada
   
HT3:
A FRAMEWORK FOR DERIVING A MINIMALLY ACCEPTABLE TARGET CLINICAL PROFILE AND A MAXIMUM VALUE-BASED PRICE FOR DRUGS IN DEVELOPMENT TO MEET HEALTH TECHNOLOGY ASSESSMENT REQUIREMENTS
Mallick R1, Sillup GP2
1Risk Sharing Solutions, Collegeville, PA, USA, 2St. Joseph's University, Philadelphia, PA, USA
   
HT4:
IN PROMETHEUS' SHADOW: EPIDEMIOLOGICAL AND ETHICAL PERSPECTIVES ON OUTCOMES OF CARDIOPULMONARY RESUSCITATION
Levy A1, Koning F2, Lockey R2, Bellack N3, Christie T4, Desjardins E2
1University of British Columbia, Vancouver, BC, Canada, 2Providence Health Care, Vancouver, BC, Canada, 3University of Ottawa, Vancouver, BC, Canada, 4Atlantic Health Sciences Corporation, Saint John Regional Hospital, St John, NB, Canada 

MEDICARE STUDIES I
MD1:
NONADHERENCE WITH ORAL HYPOGLYCEMICS AMONG MEDICARE PART D ENROLLEES WITH DIABETES
Yang Y, Thumula V, Pace PF, Banahan BF, Wilkin NE, Lobb WB
University of Mississippi, University, MS, USA
   
MD2:
RACIAL DISPARITIES IN ANTI-DEMENTIA MEDICATION, ANTI-DEPRESSANT, AND ANTIPSYCHOTIC USE AMONG MEDICARE BENEFICIARIES WITH ALZHEIMER'S DISEASE AND RELATED DEMENTIAS
Lin PJ1, Biddle AK2, Maciejewski ML3
1University of Maryland, Baltimore, MD, USA, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 3Center for Health Services Research in Primary Care, Durham, NC, USA
   
MD3:
EFFECT OF LIPID LOWERING DRUG USE ON HOSPITALIZATIONS, EMERGENCY ROOM VISITS, AND MORTALITY IN MEDICARE DIABETIC POPULATION
Thumula V, Yang Y, Pace PF, Banahan BF, Wilkin NE, Lobb WB
University of Mississippi, University, MS, USA
   
MD4:
THE EFFECT OF MEDICARE PART D ON INAPPROPRIATE PSYCHOTROPIC MEDICATION USE IN THE ELDERLY
Chen H, Obajuluwa T, Johnson M, Aparasu R
University of Houston, Houston, TX, USA

MODELING STUDIES
MO1:
IMPACT OF INCLUDING CARDIOVASCULAR AND RESPIRATORY OUTCOMES ON ESTIMATES OF CLINICAL AND ECONOMIC BENEFITS OF INFLUENZA VACCINATION IN THE U.S. ELDERLY POPULATION
Gao X1, Snedecor SJ1, Ethgen O2, Botteman MF1
1PharMerit North America LLC, Bethesda, MD, USA, 2GSK Biologicals, Rixensart, Belgium
   
MO2:
A SYSTEMATIC EVALUATION OF EMPIRICAL BAYES METHODS UNDER TIME CENSORED CONDITIONS
Murray JF1, Fryback DG2
1Eli Lilly and Company, Indianapolis, IN, USA, 2University of Wisconsin - Madison, Madison, WI, USA
   
MO3:
WITHDRAWN
   
MO4:
RE-EXAMINING THE SPECIFICATION OF REGRESSION MODELS OF MULTINOMIAL RESPONSES: AN APPLICATION TO PREDICTING POST-STROKE DISCHARGE DISPOSITION
Bergtold J1, Onukwugha E2
1Kansas State University, Manhattan, KS, USA, 2University of Maryland School of Pharmacy, Baltimore, MD, USA

NEUROLOGICAL DISORDERS - OUTCOMES RESEARCH & HEALTH CARE POLICY STUDIES
ND1:
COST-EFFECTIVENESS OF DISEASE-MODIFYING THERAPY FOR MULTIPLE SCLEROSIS: A POPULATION-BASED EVALUATION
Noyes K1, Bajorska A1, Chappel AR2, Schwid S1, Mehta LR2, Holloway R1, Dick A3
1University of Rochester School of Medicine, Rochester, NY, USA, 2University of Rochester, Rochester, NY, USA, 3The RAND Corporation, Pittsburgh, PA, USA
   
ND2:
DIRECT HEALTHCARE AND WORKLOSS BURDEN OF CHEMOTHERAPY-ASSOCIATED PERIPHERAL NEUROPATHY IN BREAST, OVARIAN, HEAD AND NECK, AND NON-SMALL CELL LUNG CANCER
Pike C1, Birnbaum HG1, Kaufman R1, Muehlenbein CE2, Pohl G2, Natale R3
1Analysis Group, Inc, Boston, MA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA, USA
   
ND3:
PRESCRIBING PATTERNS AMONG DEMENTIA PATIENTS AT THE VETERANS AFFAIRS MARYLAND HEALTH CARE SYSTEM (VAMHCS)
Rattinger GB1, DeLisle S2, Onukwugha E1, Mullins CD1
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland School of Medicine and VA Maryland Health Care System, Baltimore, MD, USA
   
ND4:
COST-UTILITY OF INTERFERON BETA-1B IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME SUGGESTIVE OF MULTIPLE SCLEROSIS: MODEL UTILIZING FIVE YEAR BENEFIT DATA
Caloyeras JP1, Harrow B1, Wang C2, Beckmann K3, Knappertz V2, Pohl C3, Miller JD1, Russell MW1, Sandbrink R3, Gondek K2
1Abt Bio-Pharma Solutions, Inc, Lexington, MA, USA, 2Bayer Healthcare Pharmaceuticals Inc, Montville, NJ, USA, 3Bayer Schering Pharma AG, Berlin, P300, Germany
 
Podium Session IV
TUESDAY, May 19, 2009
9:45AM-10:45AM
HEALTH CARE MANAGEMENT STUDIES
HM1:
EFFICIENCY AND ECONOMIC BENEFITS ASSOCIATED WITH THE USE OF A PAYER-BASED ELECTRONIC HEALTH RECORD IN AN EMERGENCY DEPARTMENT AMONG A HEALTH INSURED POPULATION
Daniel GW1, Ewen E2, Willey VJ3, Shirazi M4, Malone DC5
1HealthCore, Wilmington, DE, USA, 2Christiana Care Health System, Newark, DE, USA, 3University of the Sciences in Philadelphia, Philadelphia, PA, USA, 4University of Arizona College of Medicine, Tucson, AZ, USA, 5University of Arizona College of Pharmacy, Tucson, AZ, USA
   
HM2:
USING DECISION MODELING TO MAP PHARMACISTS INTERVENTIONS TO OUTCOMES FOR PATIENTS WITH DIABETES
Pinto SL, Bechtol R, Zhang YJ
University of Toledo, Toledo, OH, USA
   
HM3:
IMPACT OF A SPECIALTY CARE MANAGEMENT PROGRAM ON MEDICATION ADHERENCE AND HEALTH CARE UTILIZATION AMONG NON-ELDERLY ADULTS WITH MULTIPLE SCLEROSIS
Yu J, Tan H, Singer J
HealthCore, Inc, Wilmington, DE, USA
   
HM4:
THE IMPACT OF A PHARMACIST-PROVIDED TELEPHONE MEDICATION THERAPY MANAGEMENT PROGRAM ON MEDICATION AND HEALTH-RELATED PROBLEMS, MEDICATION ADHERENCE, AND TOTAL DRUG COSTS AMONG MEDICARE BENEFICIARIES: A 6-MONTH FOLLOW-UP
Moczygemba LR1, Barner JC2, Lawson KA2, Brown CM2, Gabrillo E3, Godley PJ4, Johnsrud M2
1Virginia Commonwealth University, Richmond, VA, USA, 2University of Texas at Austin, Austin, TX, USA, 3Scott and White Health Plan, Temple, TX, USA, 4Scott and White Health System, Temple, TX, USA

MEDICARE STUDIES II
MD5:
PREDICTORS OF ENROLLMENT IN MEDICARE PART D: ARE BENEFICIARIES RATIONAL?
Lines LM1, Menzin J1, Lang K1, Korn JR1, Neumann PJ2
1Boston Health Economics, Inc, Waltham, MA, USA, 2Tufts Medical Center, Boston, MA, USA
   
MD6:
PREDICTORS OF UTILIZATION OF ACE INHIBITORS AND ANGIOTENSIN II RECEPTOR BLOCKERS AMONG MEDICARE PART D ENROLLEES WITH DIABETES
Yang Y, Thumula V, Pace PF, Banahan BF, Wilkin NE, Lobb WB
University of Mississippi, University, MS, USA
   
MD7:
DOES MEDICARE HAVE AN IMPLICIT COST-EFFECTIVENESS THRESHOLD?
Chambers J1, Neumann PJ2, Buxton MJ3
1Mapi Values, Boston, MA, USA, 2Tufts Medical Center, Boston, MA, USA, 3Brunel University, Uxbridge, Middlesex, UK
   
MD8:
OUT OF POCKET PSYCHOTROPIC PRESCRIPTION BURDEN ON ELDERLY MEDICARE BENEFICIARIES BEFORE AND AFTER THE IMPLEMENTATION OF MEDICARE PART D
Chen H1, Chaudhari S2, Aparasu R1, Johnson M1
1University of Houston, Houston, TX, USA, 2Xcenda, Palm Harbor, FL, USA

MUSCULAR-SKELETAL DISORDERS - OUTCOMES RESEARCH
MS1:
ASSESSMENT OF PREFERENCE AND SATISFACTION WITH A WEEKLY ORAL TABLET VERSUS A 6-MONTH SUBCUTANEOUS INJECTION FOR THE TREATMENT OF OSTEOPOROSIS
Kendler DL1, Gold DT2, Horne R3, Borenstein J4, Varon SF4, Man HS4, Siddhanti S4, Satram-Hoang S4, Macarios D4, Bone HG5
1Clinical Research Centre, Vancouver, BC, Canada, 2Duke University Center for the Study of Aging and Human Development, Durham, NC, USA, 3The School of Pharmacy, University of London, London, UK, 4Amgen Inc, Thousand Oaks, CA, USA, 5Michigan Bone and Mineral Clinic, Detroit, MI, USA
   
MS2:
COMBINING THE SF-36 PHYSICAL FUNCTION SCALE AND THE HEALTH ASSESSMENT QUESTIONNAIRE TO IMPROVE MEASUREMENT OF PHYSICAL FUNCTION RHEUMATOID ARTHRITIS (RA): RESULTS: FROM THE PREMIER STUDY
Hammond G1, Yarlas A1, Kosinski M1, Roy S2, Cifaldi M2
1QualityMetric Incorporated, Lincoln, RI, USA, 2Abbott Laboratories, Abbott Park, IL, USA
   
MS3:
THE IMPACT OF COMPLIANCE WITH BIOLOGIC THERAPY ON CLINICAL OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS
Tang B1, McKenzie RS1, Freedman D2, Wagner S2, Piech CT1
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2Consumer Health Sciences International, Princeton, NJ, USA
   
MS4:
SOCIETAL COST OF RHEUMATOID ARTHRITIS (RA) IN THE UNITED STATES: METHODOLOGY FOR INCORPORATING INTANGIBLE COSTS
Birnbaum H1, Pike C1, Kaufman R1, Marynchenko M2, Kidolezi Y1, Cifaldi M3
1Analysis Group, Inc, Boston, MA, USA, 2Analysis Group, Inc, Montreal, QC, Canada, 3Abbott Laboratories, Abbott Park, IL, USA

QUALITY OF LIFE & UTILITY STUDIES
QL1:
COMPARISON BETWEEN THE EQ-5D AND THE SEVEN DERIVED HEALTH UTILITIES IN STROKE PATIENTS USING A NATIONAL REPRESENTATIVE SAMPLE IN THE UNITED STATES
Nichol MB, Wu J, Gu NY
University of Southern California, Los Angeles, CA, USA
   
QL2:
DEVELOPMENT OF AN ITEM BANK FOR A COMPUTER ADAPTIVE MEASURE OF FUNCTIONAL COGNITION FOR STROKE
Velozo CA1, Duncan P2, Wang JH3, Donovan NJ4, Heaton SC3, Kendall DL5, Kwon S6, Singletary FF7, Seago R8, Garretson KN9, Agonis JK7
1University of Florida/Department of Veterans Affairs, Gainesville, FL, USA, 2Duke University, Durham, NC, USA, 3University of Florida, Gainesville, FL, USA, 4Louisiana State University, Baton Rouge, LA, USA, 5University of Washington, Seattle, WA, USA, 6South Carolina College of Pharmacy - MUSC Campus, Charleston, SC, USA, 7Brooks Center for Rehabilitation Studies, Jacksonville, FL, USA, 8CNS Healthcare, Jacksonville, FL, USA, 9Brooks Rehabilitation Hospital, Jacksonville, FL, USA
   
QL3:
ESTIMATION OF UTILITY VALUES FOR DIABETES-RELATED COMPLICATIONS ON QUALITY OF LIFE FOR PATIENTS WITH TYPE-2 DIABETES IN ONTARIO, CANADA
O'Reilly D1, Xie F1, Pullenayegum E1, Gerstein H2, Blackhouse G1, Tarride JE1, Goeree RA1
1McMaster University, Hamilton, ON, Canada, 2McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
   
QL4:
VALIDATION OF THE TREATMENT RELATED IMPACT MEASURE FOR DIABETES TREATMENT AND DEVICE; TRIM-DIABETES AND TRIM-DIABETES DEVICE
Brod M1, Hammer M2, Christensen T2, Bushnell D3
1The BROD GROUP, Mill Valley, CA, USA, 2Novo Nordisk A/S, Bagsværd, Denmark, 3Health Research Associates, Inc, Mountlake Terrace, WA, USA

RISK ASSESSMENT STUDIES
RA1:
CAN THE PUBLIC'S RISK PREFERENCE WHEN WEIGHING A DRUG'S RISK/BENEFIT BE TRUSTED?
Wilson L, Pelletier D, Motter C, Basu R, Owen M, Kuan RK, Cheng Y
University of California, San Francisco, San Francisco, CA, USA
   
RA2:
RISK OF DIABETES ASSOCIATED WITH THE USE OF ATYPICAL ANTIPSYCHOTICS IN CHILDREN AND ADOLESCENTS - A TEXAS MEDICAID STUDY 
Nagar SP, Mehta S, Zweifel P, Chen H
University of Houston, Houston, TX, USA 
   
RA3:
A BAYESIAN DECISION-ANALYTIC ECONOMIC MODEL TO OPTIMIZE ALLOCATION OF RISK IN PAY-FOR-PERFORMANCE PAYMENT ARRANGEMENTS
Mallick R1, Hollenbeak C2
1Risk Sharing Solutions, Collegeville, PA, USA, 2Penn State College of Medicine, Hershey, PA, USA
   
RA4:
METABOLIC SYNDROME RISK FACTORS FOR NATIVE BORN AND FIRST GENERATION ADOLESCENTS (12-17) IN THE UNITED STATES
Hufstader MA1, Sias S1, Vaidya V2, White-Means S1
1University of Tennessee Health Science Center, Memphis, TN, USA, 2University of Tennessee, Memphis, TN, USA
   

RESPIRATORY-RELATED DISORDERS - OUTCOMES RESEARCH & HEALTH CARE POLICY STUDIES
RR1:
QUARTERLY ASSESSMENT OF SHORT ACTING ß-AGONIST USE AS A PREDICTOR OF SUBSEQUENT HEALTH CARE SERVICES USE FOR ASTHMATICS IN THE U.S.
Blanchette CM1, Silver H1, Petersen H1, Kamble S2, Meddis D3, Gutierrez B3
1Lovelace Respiratory Research Institute, Albuquerque, NM, USA, 2The University of North Carolina at Charlotte, Charlotte, NC, USA, 3AstraZeneca, Wilmington, DE, USA
   
RR2:
HEALTH CARE UTILIZATION AND COST OF COPD IN A MEDICAID POPULATION: THE ROLE OF CO-MORBID CONDITIONS
Lin PJ, Shaya FT
University of Maryland, Baltimore, MD, USA
   
RR3:
USE OF HEALTH CARE SERVICES IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATED WITH BUDESONIDE/FORMOTEROL VIA DRY POWDER INHALER (BUD/FM DPI) VERSUS TIOTROPIUM DPI
Blais L1, Forget A2, Ramachandran S3
1Université de Montréal, Montreal, QC, Canada, 2Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada, 3AstraZeneca LP, Wilmington, DE, USA
   
RR4:
OUTCOMES ASSOCIATED WITH TIOTROPIUM USE IN COPD PATIENTS
Lee TA1, Wilke CT2, Joo M3, Stroupe KT4, Krishnan JA5, Schumock GT2, Pickard AS2
1Hines VA Hospital and Northwestern University, Chicago, IL, USA, 2College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA, 3Hines VA Hospital and University of Illinois at Chicago, Chicago, IL, USA, 4Midwest Center for Health Services & Policy Research, Hines, IL, USA, 5University of Chicago, Chicago, IL, USA

Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2010 International Society for Pharmacoeconomics and Outcomes Research. All rights reserved under International and Pan-American Copyright Conventions. 
Website design by Eagle Systems USA, Inc.